Traders Buy Agilent Technologies (A) on Weakness

Traders purchased shares of Agilent Technologies (NYSE:A) on weakness during trading on Tuesday. $46.48 million flowed into the stock on the tick-up and $21.04 million flowed out of the stock on the tick-down, for a money net flow of $25.44 million into the stock. Of all stocks tracked, Agilent Technologies had the 33rd highest net in-flow for the day. Agilent Technologies traded down ($0.71) for the day and closed at $64.84

A number of brokerages have recently commented on A. Morgan Stanley boosted their price objective on Agilent Technologies from $90.00 to $95.00 and gave the stock an “overweight” rating in a research report on Monday, April 2nd. Zacks Investment Research raised Agilent Technologies from a “hold” rating to a “buy” rating and set a $72.00 price objective for the company in a research report on Wednesday, April 4th. ValuEngine raised Agilent Technologies from a “hold” rating to a “buy” rating in a research report on Thursday, March 1st. JPMorgan Chase boosted their price objective on Agilent Technologies from $75.00 to $80.00 and gave the stock an “overweight” rating in a research report on Thursday, February 15th. Finally, Cowen raised Agilent Technologies from a “market perform” rating to an “outperform” rating in a research report on Tuesday, May 15th. Three equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. Agilent Technologies has a consensus rating of “Buy” and a consensus price target of $72.20.

The company has a quick ratio of 2.88, a current ratio of 3.32 and a debt-to-equity ratio of 0.39. The company has a market cap of $20.74 billion, a price-to-earnings ratio of 27.47, a P/E/G ratio of 2.24 and a beta of 1.32.

Agilent Technologies (NYSE:A) last issued its quarterly earnings data on Monday, May 14th. The medical research company reported $0.65 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.64 by $0.01. Agilent Technologies had a return on equity of 18.01% and a net margin of 5.02%. The company had revenue of $1.21 billion during the quarter, compared to analysts’ expectations of $1.21 billion. During the same quarter in the previous year, the business earned $0.58 earnings per share. The firm’s revenue for the quarter was up 9.4% on a year-over-year basis. analysts expect that Agilent Technologies will post 2.67 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Wednesday, July 25th. Stockholders of record on Tuesday, July 3rd will be paid a dividend of $0.149 per share. This represents a $0.60 annualized dividend and a dividend yield of 0.92%. The ex-dividend date of this dividend is Monday, July 2nd. Agilent Technologies’s dividend payout ratio (DPR) is presently 25.42%.

In related news, VP Rodney Gonsalves sold 6,825 shares of the company’s stock in a transaction on Tuesday, March 13th. The stock was sold at an average price of $71.23, for a total transaction of $486,144.75. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider Patrick Kaltenbach sold 6,875 shares of the company’s stock in a transaction on Monday, March 12th. The stock was sold at an average price of $71.38, for a total value of $490,737.50. The disclosure for this sale can be found here. Insiders have sold 22,700 shares of company stock valued at $1,586,452 in the last 90 days.

A number of hedge funds have recently made changes to their positions in A. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. grew its holdings in Agilent Technologies by 1.6% in the fourth quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 48,835 shares of the medical research company’s stock valued at $3,385,000 after purchasing an additional 771 shares during the last quarter. Signature Estate & Investment Advisors LLC grew its holdings in Agilent Technologies by 7.3% in the fourth quarter. Signature Estate & Investment Advisors LLC now owns 11,406 shares of the medical research company’s stock valued at $764,000 after purchasing an additional 773 shares during the last quarter. Brinker Capital Inc. grew its holdings in Agilent Technologies by 14.2% in the first quarter. Brinker Capital Inc. now owns 6,334 shares of the medical research company’s stock valued at $424,000 after purchasing an additional 788 shares during the last quarter. Bamco Inc. NY grew its holdings in Agilent Technologies by 2.9% in the first quarter. Bamco Inc. NY now owns 28,808 shares of the medical research company’s stock valued at $1,927,000 after purchasing an additional 808 shares during the last quarter. Finally, Schroder Investment Management Group grew its holdings in Agilent Technologies by 1.9% in the first quarter. Schroder Investment Management Group now owns 44,623 shares of the medical research company’s stock valued at $2,985,000 after purchasing an additional 831 shares during the last quarter.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; microfluidics based automated electrophoresis products; cell analysis plate based assays; laboratory software and informatics systems; laboratory automation; dissolution testing; vacuum pumps; and measurement technologies.

Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply